Arrowhead plummets on FDA partial hold
Shares of biotech Arrowhead Research plunged 28% on 12 January after the company disclosed the FDA had imposed a partial clinical hold on a trial of the firm's chronic hepatitis B infection drug ARC-520.
Shares of biotech Arrowhead Research plunged 28% on 12 January after the company disclosed the FDA had imposed a partial clinical hold on a trial of the firm's chronic hepatitis B infection drug ARC-520.